Analytical method development and validation for the estimation of Furosemide an anti-diuretic in Furosemide injection diluted with normal saline in presence of impurities by RP-HPLC

Anandakumar Karunakaran , Sree Ishwarya Sudharsan , Ramesh Jayaprakash , Senthil Kumar Raju , Sindhuja Venkatachalam and Anjana Elampulakkadu

Abstract
This study was aimed to establish a simple, accurate, precise, robust and rapid reverse phase high performance liquid chromatographic method for the estimation of Furosemide in Furosemide injection diluted with normal saline and it was validated as per the parameters mentioned in the ICH guidelines such as system suitability, linearity, accuracy, precision, specificity, ruggedness and robustness and solution stability. The optimized chromatographic HPLC analysis was performed on Waters e2695 system equipped with Inertsil ODS-3V C18 column (250 cm x 150 mm; 5 µm particle size), with a mixture of 1% glacial acetic acid and acetonitrile in the ratio of 50%:50% v/v as the mobile phase, at the flow rate of 1.0 mL/min. The detection was performed at the wavelength of 272 nm and the retention time of Furosemide was found to be 7.03 min. The calibration plot gave linear relationship over the concentration range of 10-120 µg/mL with correlation coefficient of r² = 0.9998. The percentage purity of Furosemide in the given formulation was found to be 103.56 + 0.6546. The amount of furosemide in the given formulation for intraday and interday was found to be 102.45 + 0.2291 and 102.67 + 0.4041, respectively. The accuracy of the proposed method was determined by recovery studies and was found to be in the range of 100.14% to 101.01%. This indicates that there is no inteference was observed due to excipients used in formulation. The percentage of RSD was found to be less than 2 for all the parameters. All the impurities peak were separated well and no inteference were found with the retention time of Furosemide. The results of robustness, ruggedness and solution stability were found to be within the acceptance limit. Hence, the developed method was found to be simple, linear, accurate, precise, robust, rapid method for the analysis of Furosemide in Furosemide injection diluted with normal saline. In addition, the main feature of the developed method is lower run time with less solvent consumption.

Keywords
Furosemide; Method development; Furosemide injection; ICH guidelines; Impurities.

DOI
10.21472/bjbs(2021)081805

Full text
PDF

References
Alfred-Ugbenbo, D.; Zdoryk, O. A.; Georgiyants, V. A. Validation of analytical method for determination of Furosemide in extemporaneous syrup. Medical and Clinical Chemistry, v. 19, no. 2, p. 5-1, 2017. https://doi.org/10.11603/mcch.2410-681X.2017.v0.i2.7859

Amin, M. K. R.; Patel, D. R.; Shah, R. J.; Amin, J. M.; Jain, N.; Jain, D. K. Estimation of Amiloride and Furosemide in human plasma using high performance liquid chromatography. Der Pharmacia Sinica, v. 1, no. 3, p. 117-125, 2010.

Bove, T.; Belletti, A.; Putzu, A.; Pappacena, S.; Denaro, G.; Landoni, G.; Bagshaw, S. M.; Zangrillo, A. Intermittent Furosemide administration in patients with or at risk for acute kidney injury: Meta-analysis of randomized trials. PLoS ONE, v. 13, no. 4, p. 1-18, 2018. https://doi.org/10.1371/journal.pone.0196088

BP - British Pharmacopoeia Commission Office. British Pharmacopoeia. London: British Pharmacopoeia, 2011. v. 1. p. 978-979.

Brayfield, A. E. Martindale: The complete drug reference. 37. ed. New York: Pharmaceutical Press, 2011. v. A. p. 1421-1422.

Brunton, L. Goodman & Gilman's: The pharmacological basics of therapeutics. 12. ed. New York: McGraw Hill, 2011.

Chawla, L. S.; Davison, D. L.; Brasha-Mitchell, E.; Koyner, J. L.; Arthur, J. M.; Shaw, A. D.; Tumlin, J. A.; Trevino, S. A.; Kimmel, P. L.; Seneff, M. G. Development and standardization of a Furosemide stress test to predict the severity of acute kidney injury. Critical Care, v. 17, R-207, p. 1-9, 2013. https://doi.org/10.1186/cc13015

Chinaka, C. N.; Nwachukwu, N. Comparative in vitro quality assessment of five brands of Furosemide tablets marketed in Port Harcourt, Nigeria. Nigerian Journal of Pharmaceutical Research, v. 13, no. 2, p. 97-104, 2017.

Code Q2 (R1) ICH Guideline. Text on validation of analytical procedure. Canada: ICH Guidelines, 2015.

Costa, L. F.; Alcanfor, S. K. B.; Oliveira, A. L. Desenvolvimento e validação de método de quantificação de Furosemida por RMN de ¹H. Revista Virtual de Química, v. 8, no. 5, p. 1683-1692, 2016.

Darweesh, A. S. Simultaneous determination of Sulfanilamide and Furosemide by using derivative spectrophotometry. Ibn Al-Haitham Journal for Pure & Applied Sciences, v. 29, no. 2, p. 240-253, 2016.

Dhayat, N. A.; Gradwell, M. W.; Pathare, G.; Anderegg, M.; Schneider, L.; Luethi, D.; Mattmann, C.; Moe, O. W.; Vogt, B.; Fuster, D. G. Furosemide/Fludrocortisone test and clinical parameters to diagnose incomplete distal renal tubular acidosis in kidney stone formers. Clinical Journal of American Society of Nephrology, v. 12, no. 9, p. 1507-1517, 2017. https://doi.org/10.2215/cjn.01320217

Duffy, M.; Jain, S.; Harrell, N.; Kothari, N.; Reddi, A. S. Albumin and Furosemide combination for management of edema in Nephrotic Syndrome: A review of clinical studies. Cells, v. 4, p. 622-630, 2015. https://www.mdpi.com/2073-4409/4/4/622

EDQM - European Directorate for the Quality of Medicines & Health Care. European Pharmacopoeia. 8. ed. France: EDQM, 2014. v. 2. p. 2309-2310.

Gahandule, M.; Banerjee, S. K. Development of UV spectrophotometric methods and validation for estimation of Furosemide in bulk and tablet dosage form by absorbance maxima and Area Under the Curve Method. International Journal of Advances in Pharmaceutics, v. 5, no. 6, p. 160-170, 2016.

Gallignani, M.; Rondon, R. A.; Ovalles, J. F.; Brunetto, R. M. Transmission FTIR derivative spectroscopy for estimation of Furosemide in raw material and tablet dosage form. Acta Pharmaceutica Sinica B, v. 4, no. 5, p. 376-383, 2014. https://doi.org/10.1016/j.apsb.2014.06.013

Gandhi, S.; Mosleh, W.; Myers, R. B. H. Hypertonic saline with Furosemide for the treatment of acute congestive heart failure: A systematic review and meta-analysis. International Journal of Cardiology, v. 173, p. 139-145, 2014. https://doi.org/10.1016/j.ijcard.2014.03.020

Gu, G.; Zhang, Y.; Lu, R.; Cul, W. Additional furosemide treatment beyond saline hydration for the prevention of contrast-induced nephropathy: A meta-analysis of randomized controlled trials. International Journal of Clinical and Experimental Medicine, v. 8, no. 1, p. 387-394, 2015.

Gulbis, B. E.; Spencer, A. Efficacy and safety of a Furosemide continuous infusion following cardiac surgery. Annals Pharmacotherapy, v. 40, p. 1797-1803, 2006. https://doi.org/10.1345/aph.1g693

Haddock, B.; Larsson, H. B. W.; Francis, S.; Andersen, U. B. Human renal response to Furosemide: Simultaneous oxygenation and perfusion measurements in cortex and medulla. Acta Physiologica, v. 227, no. 1, e13292, 2019. https://doi.org/10.1111/apha.13292

Hashemian, F.; Ghorbanian, M. A.; Hashemian, F.; Mortazav, S. A.; Sheikhi, M.; Jahanshahi, J.; Poorolajal, J. Effect of topical Furosemide on rhinosinusal polyposis relapse after endoscopic sinus surgery a randomized clinical trial. JAMA Otolaryngology - Head & Neck Surgery, v. 142, no. 11, p. 1045-1049, 2016. https://doi.org/10.1001/jamaoto.2016.1249

Ho, K. M.; Power, B. M. Benefits and risks of Furosemide in acute kidney injury. Anaesthesia, v. 65, p. 283-293, 2010. https://doi.org/10.1111/j.1365-2044.2009.06228.x

IP - The Indian Pharmacopoeia Commission. Indian Pharmacopoeia. 8. ed. Ghaziabad: The Indian Pharmacopoeia Commission, 2018. v. 2. p. 133-2135.

Kaynak, M. S.; Sahln, S. Development and validation of a RP-HPLC method for determination of solubility of Furosemide. Turkish Journal of Pharmaceutical Sciences, v. 10, no. 1, p. 25-34, 2013.

Kher, G.; Ram, V. R.; Kher, M.; Hitendra, J. Development and validation of a HPTLC method for simultaneous determination of Furosemide and Spironolactone in its tablet formulation. Research Journal of Pharmaceutical, Biological and Chemical Sciences, v. 4, no. 1, p. 365-377, 2013.

Kitsios, G. D.; Mascari, P.; Ettunsi, R.; Gray, A. W. Co-administration of Furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: A meta-analysis. Journal of Critical Care, v. 4, no. 29, p. 253-259, 2014. https://doi.org/10.1016/j.jcrc.2013.10.004

Kumari, R.; Dubey, V.; Alam, S.; Singh, S. N. S.; Singh, R. Development analytical and validation of RP-HPLC method for simultaneous estimation of Amiloride Hydrochloride and Furosemide as API in their combined tablet dosage form. World Journal of Pharmacy and Pharmaceutical Sciences, v. 7, no. 3, p. 794-807, 2018.

Labriola, L.; Olinger, E.; Belge, H.; Pirson, Y.; Dahan, K.; Devuyst, O. Paradoxical response to Furosemide in uromodulin-associated kidney disease. Nephrology Dialysis Transplantation, v. 30, p. 330-335, 2015. https://doi.org/10.1093/ndt/gfu389

Liu, P.; McMenamin, Ú. C.; Spence, A. D.; Johnston, B. T.; Coleman, H. G.; Cardwell, C. R. Furosemide use and survival in patients with esophageal or gastric cancer: A population-based cohort study. BMC Cancer, v. 19, 1017, p. 1-12, 2019. https://doi.org/10.1186/s12885-019-6242-8

Lovett, L.; Nygard, G.; Dura, P.; Khalil S. K. W. An improved HPLC method for the determination of Furosemide in plasma and urine. Journal of Liquid Chromatography, v. 8, no. 9, p. 1611-1628, 1985. https://doi.org/10.1080/01483918508074082

Lumlertgul, N.; Peerapornratana, S.; Trakarnvanich, T.; Pongsittisak, W.; Surasit, K.; Chuasuwan, A.; Tankee, P.; Tiranathanagul, K.; Praditpornsilpa, K.; Tungsanga, K.; Eiam-Ong, S.; Kellum, J. A.; Srisawat, N. Early versus standard initiation of renal replacement therapy in Furosemide stress test non-responsive acute kidney injury patients (the FST trial). Critical Care, v. 22, Article number: 101, p. 1-9, 2018. https://doi.org/ 10.1186/s13054-018-2021-1

Mannam, R.; Yallamalli, I. M. RP-HPLC method for estimation of Furosemide in rabbit plasma. Journal of Chemical and Pharmaceutical Research, v. 10, no. 2, p. 1-5, 2018.

Matsue, Y.; Damman, K.; Voors, A. A.; Kagiyama, N.; Yamaguchi, T.; Kuroda, S.; Okumura, T.; Kida, K.; Mizuno, A.; Oishi, S.; Inuzuka, Y.; Akiyama, E.; Matsukawa, R.; Kato, K.; Suzuki, S.; Naruke, T.; Yoshioka, K.; Miyoshi, T.; Baba, Y.; Yamamoto, M.; Murai, K.; Mizutani, K.; Yoshida, K.; Kitai, T. Time-to-Furosemide treatment and mortality in patients hospitalized with acute heart failure. Journal of the American College of Cardiology, v. 69, no. 25, p. 3042-3051, 2017. https://doi.org/10.1016/j.jacc.2017.04.042

Maulik, B.; Ketan, D.; Shital, F. Development and validation of RP-HPLC method for simultaneous estimation of Furosemide and Spironolactone in their combined tablet dosage form. Journal of Pharmaceutical Science and Bioscientific Research, v. 2, no. 3, p. 144-147, 2012.

Mose, F. H.; Jörgensen, A. N.; Vrist, M. H.; Ekelöf, N. P.; Pedersen, E. B.; Bech, J. N. Effect of 3% saline and Furosemide on biomarkers of kidney injury and renal tubular function and GFR in healthy subjects: A randomized controlled trial. BMC Nephrology, v. 20, Article number: 200, 2019. https://doi.org/10.1186/s12882-019-1342-X

Najib, N.; Idkaidek, N.; Beshtawi, M.; Bader, M.; Admour, I.; Alam, S. M.; Zaman, Q.; Dham, R. Bioequivalence evaluation of two brands of Furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers. Biopharmaceutics & Drug Disposition, v. 24, p. 245-249, 2003. https://doi.org/10.1002/bdd.361

Naveed, S.; Qamar, F.; Zainab, S. Simple UV spectrophotometric assay of Furosemide. Journal of Innovations in Pharmaceuticals and Biological Sciences, v. 1, no. 3, p. 97-101, 2014.

Patil, S. R.; Kumar, L.; Kohli, G.; Bansal. A. K. Validated HPLC method for concurrent determination of Antipyrine, Carbamazepine, Furosemide and Phenytoin and its application in assessment of drug permeability through Caco-2 cell monolayers. Scientia Pharmaceutica, v. 80, no. 1, p. 89-100, 2012. https://doi.org/10.3797/scipharm.1109-03

Phale, M. Stress degradation studies of Furosemide and development and validation of Siam RP-HPLC Method for its quantification. World Journal of Pharmacological Research, v. 6, no. 1, p. 905-920, 2017.

Ram, R. R.; Ram, V. R.; Joshi, H. S. Analytical method validation of simultaneous determination of Spironolactone and Furosemide in tablet formulation and its statistical evaluation. International Letters of Chemistry, Physics and Astronomy, v. 42, p. 25-35, 2014. https://doi.org/10.18052/www.scipress.com/ILCPA.42.25

Ram, V. R.; Dave, P. N.; Joshi, H. S. Development and validation of a stability-indicating HPLC assay method for simultaneous determination of Spironolactone and Furosemide in tablet formulation. Journal of Chromatographic Science, v. 50, p. 721-726, 2012. https://doi.org/10.1093/chromsci/bms062

Rani, G. D.; Rani, A. R.; Venkateswarlu, P. Spectrophotometric determination of Furosimide in pharmaceutical formulations by charge transfer complex method. International Journal of ChemTech Research, v. 10, no. 3, p. 666-670, 2017.

Reddy, A. S. S. V.; Ahmed, M. J.; Shetty, A. S. K. Simultaneous determination and validation of Spironolactone and Furosemide by Second Order Derivative Method and Area Under Curve Method in bulk drug and pharmaceutical formulations. International Journal of ChemTech Research, v. 5, no. 4, p. 1875-1885, 2013.

Roth, J.; Rapaka, R. S.; Prasad, V. K. An HPLC procedure for the analysis of Furosemide in pharmaceuticals-analysis of Furosemide tablets and Furosemide injection. Analytical Letters, v. 14, no. 13, p. 1013-1030, 1981. https://doi.org/10.1080/00032718108081445

Seth, S. D.; Seth, V. Textbook of Pharmacology. 3. ed. New Delhi: Elsevier, 2009.

Shaikh, B. Development and validation of a liquid chromatographic method for the determination of Furosemide, a diuretic, in bovine milk. Journal of Agricultural Food Chemistry, v. 43, p. 2117-2121, 1995.

Shaikh, S. J.; Rao, N. N. Simultaneous estimation and forced degradation studies of Amiloride Hydrochloride and Furosemide in a pharmaceutical dosage form using Reverse-Phase High-Performance Liquid Chromatography Method. Asian Journal of Pharmaceutical and Clinical Research, v. 11, no. 7, p. 215-221, 2018. https://doi.org/10.22159/ajpcr.2018.v11i7.25783

Sila-on, W.; Na-Ranong, S.; Rakrod, S.; Ornlaor, S.; Joungmunkong, Z. Development and validation of RP-HPLC method for determination of Acetazolamide, Furosemide and Phenytoin extemporaneous suspensions. Asian Journal of Pharmaceutical Sciences, v. 11, no. 1, p. 138-139, 2016. https://doi.org/10.1016/j.ajps.2015.11.087

Şimşek, F. Ö.; Kaynak, M. S.; Şanli, N.; Şahin, S. Determination of Amlodipine and Furosemide with newly developed and validated RP-HPLC Method in commercially available tablet dosage forms. Hacettepe University Journal of the Faculty Pharmacy, no. 2, p. 145-158, 2012.

Sora, D. I.; Udrescua, Ş.; Albu, F.; David, V.; Medvedovici, A. Analytical issues in HPLC/MS/MS simultaneous assay of Furosemide, Spironolactone and Canrenone in human plasma samples. Journal of Pharmaceutical and Biomedical Analysis, v. 52, no. 5, p. 734-740, 2010. https://doi.org/10.1016/j.jpba.2010.03.004

Souza, A.; Kedor-Hackmann, E. R. M.; Santoro, M. I. R. M.; Aurora-Prado, M. S. Development of analytical method by free solution capillary electrophoresis for Furosemide under stress degradation. Separation Science Plus, v. 2, no. 7, p. 253-261, 2019.

Sullivan, S. L.; Whittem, T.; Morley, P. S.; Hinchcliff, K. W. A systematic review and meta-analysis of the efficacy of Furosemide for exercise-induced pulmonary haemorrhage in thoroughbred and standard bred racehorses. Equine Veterinary Journal, v. 47, p. 341-349, 2015.

Supriya, P.; Patel, S. G.; Dhobale, S. M. Estimation of Frusemide in bulk and tablet formulation by UV spectrophotometric Area Under Curve Method. International Research Journal of Science & Engineering, v. A3, p. 96-100, 2018.

Tandel, J. N. Development and validation of RP-HPLC Method for the simultaneous determination of Amiloride Hydrochloride and Furosemide in pure and pharmaceutical dosage form. Eurasian Journal of Analytical Chemistry, v. 12, no. 4, p. 385-394, 2017.

USP-NF - The United States Pharmacopoeia-The National Formulary. The Official Compendia of Standards. Rockville, MD: The United Stated Pharmacopoeial Convention, 2008. v. 2.

Vasco, R. F. V.; Moyses, R. M. A.; Zatz, R. Elias, R. M. Furosemide increases the risk of hyperparathyroidism in chronic kidney disease. American Jourbnal of Nephrology, v. 43, p. 421-430, 2016. https://doi.org/10.1159/000446449

Widdifield, C. M.; Robson, H.; Hodgkinson, P. Furosemide's one little hydrogen atom: NMR crystallography structure verification of powdered molecular organics. Chemical Communication, v. 52, p. 6685-6688, 2016. https://doi.org/10.1039/C6CC02171A

Youm, I.; Youan, B.-B. C. Validated reverse-phase high-performance liquid chromatography for quantification of Furosemide in tablets and nanoparticles. Journal of Analytical Methods in Chemistry, v. 2013, Article ID 207028, p. 1-9, 2013. https://doi.org/10.1155/2013/207028

Zeng, B.; Nguyen, K.; Sherma, J. Development of quantitative HPTLC-densitometry methods following a model approach for transfer of TLC screening methods for pharmaceutical products of Atenolol, Chloramphenicol, Furosemide, Glibenclamide, Penicillin V Potassium, and Praziquantel. Journal of Liquid Chromatography & Related Technologies, v. 41, no. 6, p. 324-332, 2018. https://doi.org/10.1080/10826076.2018.1448689


ISSN 2358-2731